Banner Rotation

Login

Login   

Kolumnen

mehr...
Markus Fugmann: 19.11.08 13:01 Update Wochenausblick...
Norbert Lohrke: 19.11.08 08:56 Freenet vor hartem Winter
 Renditetrader: 18.11.08 13:35 G20 Mitglieder sind ratlos...

Börsenbrief des Tages

mehr...

Beitrag versenden

Zurück
Sie empfehlen ein Beitrag aus dem Thema: GRANT LIFE SCI.

Beitrag versenden

 

Der zu versendende Beitrag

#18583 von  bidandask07 Erstellt am: 02.07.07 07:37:02 Beitrag Nr.: 18583 Weitere Beiträge
Dieser Beitrag:

schon komisch, habe beim googeln folgendes gefunden...  darunter war aber auch die merkwürdige Page verzeichnet

 

Beim Googlen gefunden:

Grant Life Sciences, Inc., a development stage company, engages in the development of antibody-based screening tests to screen woman for cervical cancer and pre-cancerous conditions. Its tests detect the presence of various antibodies that appear when cervical cancer or pre-cancerous conditions are present in the body by analyzing a small amount of the patient’s blood. Grant Life also holds rights to diagnostic devices for HIV-1, HIV-2, and dengue fever testing; and a proprietary colloidal gold reagent, an ingredient used by manufacturers of rapid tests. The company was founded in 1998 and is based in Los Angeles, California.




Web Address
http://www.grantlifesciences.comsmileysmiley

Email
info@grantlifesciences.com

Phone
213-637-5692

FAX
213-637-5691

Contact
Michael Ahlin VP/DIR





See Also: Historical Stats
See Also: Medical Laboratories & Research Page

Other Company Info: Goldmood Company Index
Other Company Info: Main Menu


More Research Links for this Company
Yahoo Lycos Fool MSN Nasdaq OTC Reuters
ClearStation MarketWatch Stockhouse Edgar TSX SEC Google


For the nine months ended 30 September 2006, Grant Life Sciences, Inc. reported no revenue. Net loss fell 43% to $7.5M. Revenues reflect the Company being in the development stage. Lower loss reflects a decrease in general & administrative expenses, lower research & development expenditure, a decrease in change in fair value related to adjustment of derivative & warrant liability to fair value of underlying securities expenses.


Quelle: http://www.goldmood.com/cosmos/h/GLIF.OB.html